Abstract
GEN EdgeVol. 5, No. 1 Drug DiscoveryAbsci Eyes IND for Platform's First de novo Antibody within Two YearsCompany shares expanded data showing its antibody models achieved higher binding rates than sequences from public databasesAlex PhilippidisAlex PhilippidisSearch for more papers by this authorPublished Online:12 May 2023https://doi.org/10.1089/genedge.5.1.72AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Alex Philippidis.Absci Eyes IND for Platform's First de novo Antibody within Two Years.GEN Edge.Jan 2023.374-377.http://doi.org/10.1089/genedge.5.1.72Published in Volume: 5 Issue 1: May 12, 2023PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
